Medtronic PLC $MDT Shares Sold by American Century Companies Inc.

American Century Companies Inc. lowered its holdings in shares of Medtronic PLC (NYSE:MDT) by 14.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,356,994 shares of the medical technology company’s stock after selling 1,081,458 shares during the period. American Century Companies Inc. owned approximately 0.50% of Medtronic worth $554,139,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Gilbert & Cook Inc. grew its position in Medtronic by 1.9% in the 2nd quarter. Gilbert & Cook Inc. now owns 6,103 shares of the medical technology company’s stock valued at $532,000 after buying an additional 114 shares in the last quarter. Red Spruce Capital LLC raised its position in shares of Medtronic by 0.5% during the 2nd quarter. Red Spruce Capital LLC now owns 23,707 shares of the medical technology company’s stock worth $2,067,000 after buying an additional 118 shares in the last quarter. Certior Financial Group LLC lifted its stake in shares of Medtronic by 3.7% in the 1st quarter. Certior Financial Group LLC now owns 3,450 shares of the medical technology company’s stock worth $310,000 after acquiring an additional 122 shares during the period. PrairieView Partners LLC boosted its holdings in shares of Medtronic by 3.6% in the second quarter. PrairieView Partners LLC now owns 3,726 shares of the medical technology company’s stock valued at $324,000 after acquiring an additional 128 shares in the last quarter. Finally, Motco increased its stake in shares of Medtronic by 27.0% during the first quarter. Motco now owns 635 shares of the medical technology company’s stock valued at $57,000 after acquiring an additional 135 shares during the period. Institutional investors own 82.06% of the company’s stock.

Medtronic Stock Up 1.8%

MDT stock opened at $101.16 on Friday. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50. The firm has a market capitalization of $129.76 billion, a P/E ratio of 27.87, a P/E/G ratio of 2.42 and a beta of 0.77. Medtronic PLC has a 52-week low of $79.29 and a 52-week high of $102.59. The company’s 50 day simple moving average is $95.04 and its 200-day simple moving average is $90.94.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.05. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The firm had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. During the same period in the previous year, the firm earned $1.26 earnings per share. Medtronic’s quarterly revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities research analysts anticipate that Medtronic PLC will post 5.46 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Needham & Company LLC restated a “hold” rating on shares of Medtronic in a research report on Thursday, August 14th. Citigroup lifted their price target on Medtronic from $101.00 to $112.00 and gave the company a “buy” rating in a research report on Tuesday, October 7th. Wells Fargo & Company upped their price objective on Medtronic from $100.00 to $114.00 and gave the company an “overweight” rating in a report on Wednesday. Stifel Nicolaus raised their target price on Medtronic from $90.00 to $105.00 and gave the company a “hold” rating in a research note on Thursday, October 9th. Finally, Leerink Partners set a $120.00 price target on shares of Medtronic and gave the company an “outperform” rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and twelve have given a Hold rating to the company. Based on data from MarketBeat, Medtronic presently has an average rating of “Moderate Buy” and an average price target of $109.72.

Insider Buying and Selling at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 8,605 shares of the business’s stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the completion of the sale, the executive vice president directly owned 35,615 shares of the company’s stock, valued at $3,261,621.70. The trade was a 19.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director William R. Jellison purchased 2,500 shares of the company’s stock in a transaction dated Monday, August 25th. The shares were acquired at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the purchase, the director owned 5,000 shares in the company, valued at $461,850. The trade was a 100.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 0.26% of the stock is currently owned by company insiders.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.